Significance of <i>BRCA2</i> and <i>RB1</i> Co-loss in Aggressive Prostate Cancer Progression
Goutam Chakraborty(National Centre for Cell Science), Philip W. Kantoff(Convergent Science (United States)), Joshua Armenia(AstraZeneca (United Kingdom)), Kalyani Chadalavada(Memorial Sloan Kettering Cancer Center), Yuki Yoshikawa(Hiroshima Prefectural Hospital), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Lorelei A. Mucci(American Cancer Society), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Wassim Abida(Memorial Sloan Kettering Cancer Center), Kazumasa Komura(Kawasaki Medical School), Nabeela Khan(Memorial Sloan Kettering Cancer Center), Subhiksha Nandakumar(Memorial Sloan Kettering Cancer Center), Lina Jehane(Memorial Sloan Kettering Cancer Center), Rahim Hirani(New York Medical College), Yu Chen(Guangdong Academy of Medical Sciences), Mohammad Atiq(Memorial Sloan Kettering Cancer Center)
Cited by 114
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study
|The Lancet Public Health|2020|2.3k